Table 2.
Comorbidities in our patients treated with ocrelizumab (n = 37/60).
| Type of comorbidity | Diagnosis | n |
|---|---|---|
| Cardiovascular risk factors (N = 20, 33%) | Smoker | 4 |
| Diabetes mellitus | 4 | |
| Morbid obesity | 5 | |
| High blood pressure | 2 | |
| Dyslipidaemia | 4 | |
| Obstructive sleep apnea | 1 | |
| Autoimmune (n = 4, 6%) | Autoimmune thyroid disease | 3 |
| Inflammatory bowel disease | 1 | |
| Psychiatric disorder (n = 3, 5%) | Depression | 3 |
| Cardiac disease (n = 1, 1.6%) | Arrhythmia (AF) | 1 |
| Neurological diseases (n = 3, 5%) | Epilepsy | 3 |
| Surgical procedures (n = 6, 10%) | Bariatric surgery | 5 |
| Cholecystectomy | 1 | |
| Others (n = 42, 70%) | G6PD deficiency | 1 |
| Vitamin d deficiency | 40 | |
| Vitamin b12 deficiency | 1 |